Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACBMNC for Digestive System in Preterm Neonates
NCT05138276Phase 1Unknown
- Sponsor
- Guangdong Women and Children Hospital
- Start
- Sep 2021
- Primary completion
- Dec 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of autologous cord blood mononuclear cells in necrotizing enterocolitis (NEC) (2 arms), sponsored by Guangdong Women and Children Hospital. Primary endpoint: Occurrence of Necrotizing Enterocolitis at 1 year. Status: unknown.
02
Drugs
autologous cord blood mononuclear cells
03
Conditions
necrotizing enterocolitis (NEC)
Beyond the preview
Go deeper on NCT05138276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05138276.